PTJ
CCCC icon

Paul Tudor Jones’s C4 Therapeutics CCCC Stock Holding History

Paul Tudor Jones’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,162
Closed -$46.9K – 2736
2024
Q2 		$46.9K Buy
+10,162
New +$60.6K ﹤0.01% 2230
2023
Q4 		– Sell
-15,223
Closed -$28.3K – 2404
2023
Q3 		$28.3K Buy
+15,223
New +$46.4K ﹤0.01% 2200
2023
Q2 		– Sell
-23,966
Closed -$75K – 2471
2023
Q1 		$75K Buy
+23,966
New +$141K ﹤0.01% 2274
2022
Q4 		– Sell
-24,134
Closed -$212K – 2428
2022
Q3 		$212K Buy
24,134
+14
+0.1% +$145 ﹤0.01% 2028
2022
Q2 		$182K Buy
+24,120
New +$212K ﹤0.01% 1846
2022
Q1 		– Sell
-21,283
Closed -$685K – 2071
2021
Q4 		$685K Buy
+21,283
New +$842K 0.01% 1250

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Paul Tudor Jones's CCCC Position: Q3 2024 in Review

Paul Tudor Jones sold out of C4 Therapeutics (CCCC) in Q3 2024, closing a stake of 10,162 shares — an estimated $46.9K sold.

Paul Tudor Jones first reported a position in CCCC in Q4 2021 and held it in 6 quarters. The position peaked at $685K in Q4 2021. 118 funds tracked by Wall St. Rank hold CCCC as of Q3 2024.

  • Paul Tudor Jones reported no remaining C4 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 10,162 C4 Therapeutics shares in Q3 2024, an estimated $46.9K.
  • Paul Tudor Jones first reported a position in C4 Therapeutics in Q4 2021 and held it in 6 quarters.
  • Paul Tudor Jones's C4 Therapeutics position peaked at $685K in Q4 2021.
  • 118 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2024.

Based on Tudor Investment Corp's 13F filing for Q3 2024, filed 14 Nov 2024.